Yunhui Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yunhui Jia has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Yuanyuan Wei
Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China
4 shared publications - Yuhuai Xie
Department of Basic Veterinary Medicine, College of Veterinary Medicine, Shandong Agricultural University
3 shared publications - Zhen Zhao
Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China
3 shared publications Jiaxuan Yang
Department of Immunology, School of Basic Medical Sciences, and Department of Rheumatology, Zhongshan Hospital (X.Y., X.Z., Y.T., J.Y., Y.J., Y.X., L.C., S.C., L.W., Y.Q., Y.W.), Fudan University, Shanghai, China
2 shared publications- Lianping Cheng
Department of Immunology, School of Basic Medical Sciences, and Department of Rheumatology, Zhongshan Hospital, Fudan University , No. 130, Dong’an Road, Shanghai 200032
2 shared publications Xian Yang
Department of Immunology, School of Basic Medical Sciences, and Department of Rheumatology, Zhongshan Hospital (X.Y., X.Z., Y.T., J.Y., Y.J., Y.X., L.C., S.C., L.W., Y.Q., Y.W.), Fudan University, Shanghai, China
2 shared publications
Latest Publications
- 11 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (28) , 3736-3755
Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications
Background and Aims: Atherosclerosis is a chronic inflammatory disease of the arterial wall, where modified self-antigens cause sustained adaptive immune responses driven by clonal expansion of CD4+ effector T cells in situ. Although immune tolerance-inducing vaccination strategies show promise in animal models, their clinical translation is limited by the unclear role of adaptive immune responses in human atherosclerosis. Methods: RNA sequencing and immunohistochemistry were employed in human atherosclerotic plaques. Nuclear run-on, CRISPRi/a, RNA pull-down, ChIP-qPCR, and flow cytometry were utilized to investigate the lncRNA-dependent regulatory mechanism. Functional validation was performed in Apoe−/− mice through perivascular or intravenous siRNA delivery, as well as perivascular administration of macrophage-targeting lipid nanoparticles carrying dCas9-VP64 mRNA and the guide RNA. Results: Major histocompatibility complex class II (MHCII)-dependent antigen presentation pathways were progressively activated in lesional macrophages as human atherosclerosis advanced. This activation was associated with increased CIITA expression, driven by enhanced transcription of its antisense-lncRNA (CIITA-AS1) and alternative splicing generating a non-coding transcript. Knockdown of these two lncRNAs reduced MHCII levels in human macrophages, thereby suppressing co-cultured T-cell activation. Mechanistically, CIITA-AS1 transcription promoted CIITA expression through STAT1 recruitment. Enforcing antisense-strand transcription of Ciita in lesional macrophages up-regulated Ciita and MHCII expression, exacerbating atherosclerosis in mice. Conversely, inhibition of macrophage antigen presentation via siRNA-mediated Ciita silencing attenuated atherosclerosis by reducing T-cell-mediated inflammation. Conclusions: This study reveals that CIITA-induced antigen presentation in macrophages activates local T-cell inflammatory response, promoting plaque progression. Targeting this pathway may improve vaccination efficacy by creating anti-inflammatory niches within plaques, offering a novel therapeutic strategy for atherosclerosis.
- 11 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (28) , 3736-3755
Enhanced antigen presentation by macrophages promotes human atherosclerosis progression: therapeutic implications
Background and Aims: Atherosclerosis is a chronic inflammatory disease of the arterial wall, where modified self-antigens cause sustained adaptive immune responses driven by clonal expansion of CD4+ effector T cells in situ. Although immune tolerance-inducing vaccination strategies show promise in animal models, their clinical translation is limited by the unclear role of adaptive immune responses in human atherosclerosis. Methods: RNA sequencing and immunohistochemistry were employed in human atherosclerotic plaques. Nuclear run-on, CRISPRi/a, RNA pull-down, ChIP-qPCR, and flow cytometry were utilized to investigate the lncRNA-dependent regulatory mechanism. Functional validation was performed in Apoe−/− mice through perivascular or intravenous siRNA delivery, as well as perivascular administration of macrophage-targeting lipid nanoparticles carrying dCas9-VP64 mRNA and the guide RNA. Results: Major histocompatibility complex class II (MHCII)-dependent antigen presentation pathways were progressively activated in lesional macrophages as human atherosclerosis advanced. This activation was associated with increased CIITA expression, driven by enhanced transcription of its antisense-lncRNA (CIITA-AS1) and alternative splicing generating a non-coding transcript. Knockdown of these two lncRNAs reduced MHCII levels in human macrophages, thereby suppressing co-cultured T-cell activation. Mechanistically, CIITA-AS1 transcription promoted CIITA expression through STAT1 recruitment. Enforcing antisense-strand transcription of Ciita in lesional macrophages up-regulated Ciita and MHCII expression, exacerbating atherosclerosis in mice. Conversely, inhibition of macrophage antigen presentation via siRNA-mediated Ciita silencing attenuated atherosclerosis by reducing T-cell-mediated inflammation. Conclusions: This study reveals that CIITA-induced antigen presentation in macrophages activates local T-cell inflammatory response, promoting plaque progression. Targeting this pathway may improve vaccination efficacy by creating anti-inflammatory niches within plaques, offering a novel therapeutic strategy for atherosclerosis.
- 25 April 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 136 (9) , 985-1009
Srsf3-Dependent APA Drives Macrophage Maturation and Limits Atherosclerosis
BACKGROUND: Circulating monocytes largely contribute to macrophage buildup in atheromata, which is crucial for clearing subendothelial LDLs (low-density lipoproteins) and dead cells; however, the transitional trajectory from monocytes to macrophages in atherosclerotic plaques and the underlying regulatory mechanism remain unclear. Moreover, the role of alternative polyadenylation, a posttranscriptional regulator of cell fate, in monocyte/macrophage fate decisions during atherogenesis is not entirely understood. METHODS: To identify monocyte/macrophage subtypes in atherosclerotic lesions and the effect of alternative polyadenylation on these subtypes and atherogenesis, single-cell RNA sequencing, 3′-end sequencing, flow cytometric, and histopathologic analyses were performed on plaques obtained from Apoe −/− mouse arteries with or without myeloid deletion of Srsf3 (serine/arginine-rich splicing factor 3). Cell fractionation, polysome profiling, L-azidohomoalanine metabolic labeling assay, and metabolomic profiling were conducted to disclose the underlying mechanisms. Reprogramming of widespread alternative polyadenylation patterns was estimated in human plaques via bulk RNA sequencing. RESULTS: We identified a subset of lesional cells in a monocyte-to-macrophage transitional state, which exhibited high expression of chemokines in mice. Srsf3 deletion caused a maturation delay of these transitional cells and phagocytic impairment of lesional macrophages, aggravating atherosclerosis. Mechanistically, Srsf3 deficiency shortened 3′ untranslated regions of mitochondria-associated Aars2 (alanyl-tRNA synthetase 2), disrupting its translation. The resultant impairment of protein synthesis in mitochondria led to mitochondrial dysfunction with declined NAD + (nicotinamide adenine dinucleotide, oxidized form) levels, activation of the integrated stress response, and metabolic reprogramming in macrophages. Administering an NAD + precursor nicotinamide mononucleotide or the integrated stress response inhibitor partially restored Srsf3 -deficient macrophage maturation, and nicotinamide mononucleotide treatment mitigated the proatherosclerotic effects of Srsf3 deficiency. Consistently, Srsf3 downregulation, global 3′ untranslated region shortening, and accumulation of these transitional macrophages were associated with atherosclerosis progression in humans. CONCLUSIONS: Our study reveals that Srsf3-dependent generation of long 3′ untranslated region is required for efficient mitochondrial translation, which promotes mature phagocytic macrophage formation, thereby playing a protective role in atherosclerosis.
- 25 April 2025
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 136 (9) , 985-1009
Srsf3-Dependent APA Drives Macrophage Maturation and Limits Atherosclerosis
BACKGROUND: Circulating monocytes largely contribute to macrophage buildup in atheromata, which is crucial for clearing subendothelial LDLs (low-density lipoproteins) and dead cells; however, the transitional trajectory from monocytes to macrophages in atherosclerotic plaques and the underlying regulatory mechanism remain unclear. Moreover, the role of alternative polyadenylation, a posttranscriptional regulator of cell fate, in monocyte/macrophage fate decisions during atherogenesis is not entirely understood. METHODS: To identify monocyte/macrophage subtypes in atherosclerotic lesions and the effect of alternative polyadenylation on these subtypes and atherogenesis, single-cell RNA sequencing, 3′-end sequencing, flow cytometric, and histopathologic analyses were performed on plaques obtained from Apoe −/− mouse arteries with or without myeloid deletion of Srsf3 (serine/arginine-rich splicing factor 3). Cell fractionation, polysome profiling, L-azidohomoalanine metabolic labeling assay, and metabolomic profiling were conducted to disclose the underlying mechanisms. Reprogramming of widespread alternative polyadenylation patterns was estimated in human plaques via bulk RNA sequencing. RESULTS: We identified a subset of lesional cells in a monocyte-to-macrophage transitional state, which exhibited high expression of chemokines in mice. Srsf3 deletion caused a maturation delay of these transitional cells and phagocytic impairment of lesional macrophages, aggravating atherosclerosis. Mechanistically, Srsf3 deficiency shortened 3′ untranslated regions of mitochondria-associated Aars2 (alanyl-tRNA synthetase 2), disrupting its translation. The resultant impairment of protein synthesis in mitochondria led to mitochondrial dysfunction with declined NAD + (nicotinamide adenine dinucleotide, oxidized form) levels, activation of the integrated stress response, and metabolic reprogramming in macrophages. Administering an NAD + precursor nicotinamide mononucleotide or the integrated stress response inhibitor partially restored Srsf3 -deficient macrophage maturation, and nicotinamide mononucleotide treatment mitigated the proatherosclerotic effects of Srsf3 deficiency. Consistently, Srsf3 downregulation, global 3′ untranslated region shortening, and accumulation of these transitional macrophages were associated with atherosclerosis progression in humans. CONCLUSIONS: Our study reveals that Srsf3-dependent generation of long 3′ untranslated region is required for efficient mitochondrial translation, which promotes mature phagocytic macrophage formation, thereby playing a protective role in atherosclerosis.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 218-237
miR-223-3p Prevents Necroptotic Macrophage Death by Targeting Ripk3 in a Negative Feedback Loop and Consequently Ameliorates Advanced Atherosclerosis
BACKGROUND: The formation of large necrotic cores results in vulnerable atherosclerotic plaques, which can lead to severe cardiovascular diseases. However, the specific regulatory mechanisms underlying the development of necrotic cores remain unclear. METHODS: To evaluate how the modes of lesional cell death are reprogrammed during the development of atherosclerosis, the expression levels of key proteins that are involved in the necroptotic, apoptotic, and pyroptotic pathways were compared between different stages of plaques in humans and mice. Luciferase assays and loss-of-function studies were performed to identify the microRNA-mediated regulatory mechanism that protects foamy macrophages from necroptotic cell death. The role of this mechanism in atherosclerosis was determined by using a knockout mouse model with perivascular drug administration and tail vein injection of microRNA inhibitors in Apoe −/− mice. RESULTS: Here, we demonstrate that the necroptotic, rather than the apoptotic or pyroptotic, pathway is more activated in advanced unstable plaques compared with stable plaques in both humans and mice, which closely correlates with necrotic core formation. The upregulated expression of Ripk3 (receptor-interacting protein kinase 3) promotes the C/EBPβ (CCAAT/enhancer binding protein beta)-dependent transcription of the microRNA miR-223-3p, which conversely inhibits Ripk3 expression and forms a negative feedback loop to regulate the necroptosis of foamy macrophages. The knockout of the Mir223 gene in bone marrow cells accelerates atherosclerosis in Apoe −/− mice, but this effect can be rescued by Ripk3 deficiency or treatment with the necroptosis inhibitors necrostatin-1 and GSK-872. Like the Mir223 knockout, treating Apoe −/− mice with miR-223-3p inhibitors increases atherosclerosis. CONCLUSIONS: Our study suggests that miR-223-3p expression in macrophages protects against atherosclerotic plaque rupture by limiting the formation of necrotic cores, thus providing a potential microRNA therapeutic candidate for atherosclerosis.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 218-237
miR-223-3p Prevents Necroptotic Macrophage Death by Targeting Ripk3 in a Negative Feedback Loop and Consequently Ameliorates Advanced Atherosclerosis
BACKGROUND: The formation of large necrotic cores results in vulnerable atherosclerotic plaques, which can lead to severe cardiovascular diseases. However, the specific regulatory mechanisms underlying the development of necrotic cores remain unclear. METHODS: To evaluate how the modes of lesional cell death are reprogrammed during the development of atherosclerosis, the expression levels of key proteins that are involved in the necroptotic, apoptotic, and pyroptotic pathways were compared between different stages of plaques in humans and mice. Luciferase assays and loss-of-function studies were performed to identify the microRNA-mediated regulatory mechanism that protects foamy macrophages from necroptotic cell death. The role of this mechanism in atherosclerosis was determined by using a knockout mouse model with perivascular drug administration and tail vein injection of microRNA inhibitors in Apoe −/− mice. RESULTS: Here, we demonstrate that the necroptotic, rather than the apoptotic or pyroptotic, pathway is more activated in advanced unstable plaques compared with stable plaques in both humans and mice, which closely correlates with necrotic core formation. The upregulated expression of Ripk3 (receptor-interacting protein kinase 3) promotes the C/EBPβ (CCAAT/enhancer binding protein beta)-dependent transcription of the microRNA miR-223-3p, which conversely inhibits Ripk3 expression and forms a negative feedback loop to regulate the necroptosis of foamy macrophages. The knockout of the Mir223 gene in bone marrow cells accelerates atherosclerosis in Apoe −/− mice, but this effect can be rescued by Ripk3 deficiency or treatment with the necroptosis inhibitors necrostatin-1 and GSK-872. Like the Mir223 knockout, treating Apoe −/− mice with miR-223-3p inhibitors increases atherosclerosis. CONCLUSIONS: Our study suggests that miR-223-3p expression in macrophages protects against atherosclerotic plaque rupture by limiting the formation of necrotic cores, thus providing a potential microRNA therapeutic candidate for atherosclerosis.
- Open Access
- 7 November 2023
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 441, 02002
Analysis of 750 kV Conductors in 750 kV Substations
Two-bundled conductors are generally used in the design of 750 kV substations. Compared to two-bundled conductors, multi-bundled conductors have higher load capacity and greater start-up voltage. This paper investigates the possibility of using multi-bundled conductors instead of two-bundled conductors in 750 kV substations from both technical and economic aspects.
- 7 November 2023
- Published by EDP Sciences in E3S Web of Conferences
- Vol. 441, 02002
Open AccessAnalysis of 750 kV Conductors in 750 kV Substations
Two-bundled conductors are generally used in the design of 750 kV substations. Compared to two-bundled conductors, multi-bundled conductors have higher load capacity and greater start-up voltage. This paper investigates the possibility of using multi-bundled conductors instead of two-bundled conductors in 750 kV substations from both technical and economic aspects.
- Open Access
- 29 March 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (7) , 2357
Modulators of MicroRNA Function in the Immune System
MicroRNAs (miRNAs) play a key role in fine-tuning host immune homeostasis and responses through the negative regulation of mRNA stability and translation. The pathways regulated by miRNAs are well characterized, but the precise mechanisms that control the miRNA-mediated regulation of gene expression during immune cell-development and immune responses to invading pathogens are incompletely understood. Context-specific interactions of miRNAs with other RNA species or proteins may modulate the function of a given miRNA. Dysregulation of miRNA function is associated with various human diseases, such as cardiovascular diseases and cancers. Here, we review the potential modulators of miRNA function in the immune system, including the transcription regulators of miRNA genes, miRNA-processing enzymes, factors affecting miRNA targeting, and intercellular communication.
- 29 March 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (7) , 2357
Open AccessModulators of MicroRNA Function in the Immune System
MicroRNAs (miRNAs) play a key role in fine-tuning host immune homeostasis and responses through the negative regulation of mRNA stability and translation. The pathways regulated by miRNAs are well characterized, but the precise mechanisms that control the miRNA-mediated regulation of gene expression during immune cell-development and immune responses to invading pathogens are incompletely understood. Context-specific interactions of miRNAs with other RNA species or proteins may modulate the function of a given miRNA. Dysregulation of miRNA function is associated with various human diseases, such as cardiovascular diseases and cancers. Here, we review the potential modulators of miRNA function in the immune system, including the transcription regulators of miRNA genes, miRNA-processing enzymes, factors affecting miRNA targeting, and intercellular communication.